Skip to content

Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis

Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis: a Randomized, Double-blind, Placebo-controlled, Effective Clinical Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06514339
Enrollment
410
Registered
2024-07-23
Start date
2024-07-01
Completion date
2026-07-01
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Sepsis, Shenhuang granules, Evidence-based evaluation, Effect mechanism research

Brief summary

Sepsis is a life-threatening organ dysfunction caused by the body's dysfunctional response to infection, most patients require treatment in the ICU, and is the leading cause of death worldwide. Over the years, the development of new drugs for the treatment of sepsis has failed without significant benefit in reducing mortality, and there is currently no effective drug treatment. Therefore, sepsis is a serious disease threatening the life and health of patients, causing a huge burden to society, and is a major problem in the medical field. The pathogenesis of sepsis is complicated, and immune imbalance is the key mechanism. Suppression of host immune function may be the root cause of the increase in the long-term mortality of sepsis. Bidirectional immune regulation may be an important treatment plan to improve the survival rate and quality of life of sepsis patients. In recent years, the contribution of traditional Chinese medicine to sepsis has been highly valued at home and abroad. The treatment of sepsis by traditional Chinese medicine mainly plays the role of bidirectional immune regulation by dispelling the evil and supporting the right. Our team has achieved some results in the diagnosis and treatment of sepsis by using traditional Chinese medicine. Supported by National Natural Science Foundation of China (81774070). The team also found that magnolol can inhibit intestinal mucosal inflammation in sepsis, which was also supported by the National Natural Science Foundation of China (82174178). The team of Qhuang scholars inherit the academic experience of Zhu Liangchun, the master of Chinese medicine, warm and hot disease need not be limited to the law of wei, qi, ying, blood transmission, that is, the disease can be solved both outside and inside, breaking the three bans of warm and cold disease. On the basis of inheriting Zhu Liangchun's academic theory, the author put forward the early treatment rule of truncation and reversal, and used to cleanse the poison and save Yin in the early stage of sepsis to quickly truncate the malignant development trend of sepsis. In the COVID-19 epidemic, we have found that patients with COVID-19 sepsis have acute deficiency syndrome in the early stage of clinical syndrome, which is an important factor leading to death. The clinical efficacy and mechanism of Shenhuang Granules in sepsis caused by non-novel coronavirus infection such as bacteria need to be further studied.

Detailed description

1. Baseline data: patient's name, gender, age, enrollment diagnosis, sepsis diagnosis time, combined underlying disease, allergy history, personal history, body temperature, respiration, heart rate, blood pressure, blood oxygen saturation and other vital signs. 2. Primary outcome measure: 28-day mortality 3. Secondary outcome indicators: A. Total length of stay and ICU stay B. Total hospitalization costs and ICU hospitalization costs C. Overall mortality and ICU mortality D.28 days cumulative no mechanical ventilation time E. Information of TCM syndrome such as tongue and pulse on day 0 and day 5-7 F. TCM symptom scores on days 0 and 5-7 G. SOFA score and APACHE II score on days 0 and 5-7. 4. Other observation indicators (day 0 and 7) : A. Inflammatory markers: WBC, percentage of neutrophils, CRP, PCT, tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10); B. Main organ function indicators: BNP, TnI, creatinine, urea nitrogen, total bilirubin, direct bilirubin, indirect bilirubin, AST, ALT, arterial lactic acid; C. Coagulation indicators: PT, APTT; D. Immune function: absolute number of lymphocytes, number of CD4+T cells, number of CD8+T cells, number of B cells, number of NK cells. 5. Safety indicators: adverse reaction symptoms or adverse events (such as allergies). If you need to collect stool and blood samples, you also need to observe the following indicators, if not, please ignore. 6. Metabolomic study: Serum samples from day 0 and day 5-7 were collected for the study of the main functional components of Shenhuang granules and metabolomic analysis; 7. Intestinal microecology study: Stool samples from day 0 and day 5-7 were collected for intestinal microecology study.

Interventions

DRUGshenhuang granule

Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification.

DRUGplacebo

Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.

Sponsors

Zhejiang University
CollaboratorOTHER
Red Cross Hospital, Hangzhou, China
CollaboratorOTHER
Ningbo Hospital of Traditional Chinese Medicine
CollaboratorUNKNOWN
The First Affiliated Hospital of Zhejiang Chinese Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

This study will adopt the block randomization method to randomly assign qualified subjects to the test group or the control group in a ratio of 1:1. A central randomization system was used for randomization and drug distribution management. From randomization until the database is locked, subjects, investigators, data analysts, sponsors, and all medical personnel involved in the treatment or clinical evaluation will remain blind to the reality of the treatment. The random number table (blind bottom) used in this study will be generated by the randomization specialist and imported into the system. The random number is reproducible. The relationship between the experimental group drug or the control group simulated drug and the subjects was represented by random number and drug number. The blind bottom is kept by the randomisation Specialist and remains unknown to both subjects and investigators throughout the trial.

Intervention model description

The researchers were randomly assigned to either a trial or a control group. Experimental group: sepsis cluster therapy + Shenhuang granules, course of 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Shenhuang Granules (Tianjin Hongri Pharmaceutical Co., LTD.) : 2 times a day, 1 pack each time, 100ml of warm water (temperature about 40°C) after dissolution, oral or nasal feeding (stomach tube or intestinal tube). Control group: sepsis cluster therapy + placebo for 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Placebo (Tianjin Hongri Pharmaceutical Co., LTD.) : After dissolution of 100ml warm water (temperature about 40°C) in 1 pack twice a day, oral or nasal feeding (gastric tube or intestinal tube).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years old * Meet the diagnostic criteria of sepsis 3.0 guidelines * Sign informed consent.

Exclusion criteria

* Liver or kidney single SOFA score ≥3 points of liver and kidney dysfunction * Death is expected within 48 hours, or SOFA≥15 points, or APACHE II ≥30 points, or the patient refuses active treatment * Patients with allergic reactions to traditional Chinese medicine * Patients treated with chemotherapy or radiotherapy or high-dose immunosuppressants within the last 1 month * Participants in other clinical trials at the same time or within 30 days * Pregnant and lactating women * Patients with severe gastrointestinal bleeding, intestinal obstruction, or severe intraperitoneal pressure elevation (IAP≥20mmHg).

Design outcomes

Primary

MeasureTime frameDescription
28-day mortality rate28-dayThe proportion of deaths due to illness within 28 days after treatment began

Secondary

MeasureTime frameDescription
Total hospitalization costs and ICU hospitalization costs7 day after treatment,14 day after treatment,28 day after treatmentThe patient's total hospitalization costs and hospitalization costs in the ICU
Overall mortality and ICU mortality7 day after treatment,14 day after treatment,28 day after treatmentThe proportion of patients who died during their total hospital stay and the proportion of patients who died during their ICU stay were included
Total length of stay and ICU stay7 day after treatment,14 day after treatment,28 day after treatmentTotal length of stay and length of stay in ICU
SOFA scoreday 0,day 5-7The SOFA score uses six criteria to reflect the function of organ systems (respiratory, blood, liver, cardiovascular, nervous, and kidney) and sets each on a score of 0-4. The objective was to describe the occurrence, development and incidence of MODS
APACHE II scoreday 0,day 5-7The APACHE II score is based on 12 physiological indicators, age, and health status on a scale of 0-71. The higher the score, the more severe the reaction condition, the worse the prognosis, and the higher the expected fatality rate
28 days cumulative no mechanical ventilation time28 day after treatmentThe total time the patient spent without mechanical ventilation (such as a ventilator) in the 28 days following the start of treatment.

Other

MeasureTime frameDescription
Thrombin timeday 0,7 day after treatmentIts numerical and coagulation index significantly correlated, prothrombin time is screening test of the extrinsic coagulation pathway.
Partial activated thromboplastin timeday 0,7 day after treatmentIts value is significantly correlated with coagulation indexes, and it is the most sensitive and commonly used screening test for endogenous coagulation system.
Blood routine testday 0,7 day after treatmentIt mainly includes WBC, percentage of neutrophils,The percentages of white blood cells and neutrophils represent inflammation, with higher values indicating higher inflammation.
Adverse event tableDay 0,7 day after treatment,14 day after treatment,28 day after treatmentPatient safety during treatment was assessed by the Adverse Events Table
Changes in bile acid profile compositionDay 0, day 5-7Blood samples were collected, and the changes in the number and concentration of bile acids in the blood were analyzed to explore the changes in the composition of the bile acid spectrum before and after treatment
Immune functionday 0,7 day after treatmentIt mainly includes the absolute number of lymphocytes, the number of CD4+T cells, the number of CD8+T cells, the number of B cells, the number of NK cells and other indicators to evaluate the immune function of patients
C-reactive proteinday 0,7 day after treatmentC-reactive protein on behalf of the inflammation, the higher the value, the higher the inflammatory conditions.
Procalcitoninday 0,7 day after treatmentProcalcitonin, the degree of its increase is positively correlated with the degree of infection. Used in the identification of bacteria and viruses, to monitor the severity of the infection, is used to evaluate the therapeutic effect and prognosis of infection.
TNF-αday 0,7 day after treatmentIt is one of the cytokines involved in the inflammatory response and is used to evaluate the therapeutic effect and prognosis of infection.
interleukin-6 (IL-6), interleukin-10 (IL-10)day 0,7 day after treatmentIt is one of the cytokines involved in the inflammatory response and is used to evaluate the therapeutic effect and prognosis of infection.
Routine biochemical testsday 0,7 day after treatmentAmong them, abnormal total bilirubin, direct bilirubin, indirect bilirubin, AST, and ALT indicated liver function problems, abnormal BNP and TnI indicated heart function problems, and abnormal creatinine and urea nitrogen indicated renal function problems
Arterial lactic acidday 0,7 day after treatmentArterial lactate was significantly associated with inflammation. Inflammatory reaction period, memory increased plasma lactate levels, lactic acid leels may aggravate the inflammatory response at the same time

Countries

China

Contacts

Primary ContactWu JianNong, doctor
13777571598@163.com13777571598
Backup ContactMeng-Yuan Shen, doctor
1355759459@qq.com18261812250

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026